Exact Sciences Corp. (EXAS)

Exact Sciences Corp. (Nasdaq: EXAS) is a global leader in cancer diagnostics and molecular screening, dedicated to providing the data needed to catch cancer earlier and guide more effective treatment. Led by Chairman and CEO Kevin Conroy, the company’s mission is to eradicate cancer by making early detection a routine part of healthcare. Exact Sciences envisions a future where its multi-cancer early detection (MCED) tests become the global standard for preventative medicine. As the developer of the iconic Cologuard test, EXAS stock is a primary beneficiary of the transition toward non-invasive, high-accuracy cancer screening technologies.

The business operations of Exact Sciences in late 2025 have been defined by the successful commercial launch of "Cologuard Plus," which offers even higher sensitivity and specificity for colorectal cancer. In December 2025, EXAS stock investors cheered the inclusion of its OncoLiquid blood-based biopsy in several major payer networks, significantly expanding its total addressable market. The company’s core products include Cologuard for colon cancer and the Oncotype DX suite for breast and colon cancer treatment guidance. The future business strategy for EXAS stock involves scaling its "Cancerguard" platform, aiming to detect over 10 types of cancer from a single blood draw. Throughout 2025, the company reported its first sustained period of GAAP-level operational profitability, reflecting its maturing business model. As diagnostic technology evolves, the specialized molecular data provided by EXAS stock has become a critical link in the oncology value chain, supporting the long-term growth case for the stock.

Exact Sciences stock is listed on the Nasdaq Global Select Market under the ticker symbol EXAS. In late 2025, the EXAS stock price has shown a strong upward trend, recently trading near $78 as the market rewards its market share gains and improving margins. Analysts monitoring the EXAS stock price highlight the company’s massive data moat and its unrivaled primary care sales force. For those tracking the EXAS stock price today, key catalysts include new FDA submissions for its hereditary cancer testing pipeline. As a pioneer in the diagnostics sector, EXAS stock remains a top selection for growth-oriented healthcare investors. The performance of the EXAS stock price reflects its role as a leader in the fight against cancer.